Comprehensive transcriptomic analysis of molecularly targeted drugs in cancer for target pathway evaluation

Cancer Science

Volumn 106, Issue 7, 2015, Pages 909-920

  Mashima, Tetsuo ^a   Ushijima, Masaru ^b   Matsuura, Masaaki ^b,c   Tsukahara, Satomi ^a   Kunimasa, Kazuhiro ^a   Furuno, Aki ^a   Saito, Sakae ^a   Kitamura, Masami ^a   Soma Nagae, Taeko ^a   Seimiya, Hiroyuki ^a   Dan, Shingo ^a   Yamori, Takao ^a   Tomida, Akihiro ^a  

^a CANCER INSTITUTE   (Japan)

^b CANCER CHEMOTHERAPY CENTER   (Japan)

^c TEIKYO UNIVERSITY   (Japan)

Author keywords

Antitumor agents; Computational biology; Gene expression profiling; Molecular targeted therapy; Protein kinase inhibitors

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (4 AMINO 1 ISOPROPYL 1H PYRAZOLO[3,4 D]PYRIMIDIN 3 YL) 1H INDOL 5 OL; AFATINIB; ALECTINIB; ANTINEOPLASTIC AGENT; AXITINIB; BOSUTINIB; BUPARLISIB; CABOZANTINIB; CRIZOTINIB; DABRAFENIB; DACTOLISIB; DASATINIB; DOXORUBICIN; ERLOTINIB; EVEROLIMUS; FIRTECAN; GEFITINIB; IMATINIB; LAPATINIB; NILOTINIB; PAZOPANIB; PONATINIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TRAMETINIB; UNINDEXED DRUG; VANDETANIB; VEMURAFENIB; PROTEIN KINASE INHIBITOR; TRANSCRIPTOME;

ARTICLE; CANCER CELL; CELL PROLIFERATION; CLUSTER ANALYSIS; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; FEMALE; GENE EXPRESSION; GENETIC ANALYSIS; HT 29 CELL LINE; HUMAN; HUMAN CELL; K562 CELL LINE; MALE; MALIGNANT NEOPLASTIC DISEASE; MOLECULARLY TARGETED THERAPY; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; TRANSCRIPTOMICS; GENE EXPRESSION PROFILING; GENE ONTOLOGY; NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; GENE EXPRESSION PROFILING; GENE ONTOLOGY; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; TRANSCRIPTOME;

EID: 84936985711     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12682     Document Type: Article

References (28)

1. Torti D, Trusolino L. Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils. EMBO Mol Med 2011; 3: 623-36.
2. Cepero V, Sierra JR, Giordano S. Tyrosine kinases as molecular targets to inhibit cancer progression and metastasis. Curr Pharm Des 2010; 16: 1396-409.
3. Workman P, Al-Lazikani B, Clarke PA. Genome-based cancer therapeutics: targets, kinase drug resistance and future strategies for precision oncology. Curr Opin Pharmacol 2013; 13: 486-96.
4. Tsai CJ, Nussinov R. The molecular basis of targeting protein kinases in cancer therapeutics. Semin Cancer Biol 2013; 23: 235-42.
5. Yano S, Takeuchi S, Nakagawa T, Yamada T. Ligand-triggered resistance to molecular targeted drugs in lung cancer: roles of hepatocyte growth factor and epidermal growth factor receptor ligands. Cancer Sci 2012; 103: 1189-94.
6. Niederst MJ, Engelman JA. Bypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancer. Sci Signal 2013; 6: re6.
7. Chen ST, Thomas S, Gaffney KJ, Louie SG, Petasis NA, Schonthal AH. Cytotoxic effects of celecoxib on Raji lymphoma cells correlate with aggravated endoplasmic reticulum stress but not with inhibition of cyclooxygenase-2. Leuk Res 2010; 34: 250-3.
8. Michieli P, Di Nicolantonio F. Targeted therapies: Tivantinib-a cytotoxic drug in MET inhibitor's clothes? Nat Rev Clin Oncol 2013; 10: 372-4.
9. Lamb J, Crawford ED, Peck D et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 2006; 313: 1929-35.
10. Ushijima M, Mashima T, Tomida A et al. Development of a gene expression database and related analysis programs for evaluation of anticancer compounds. Cancer Sci 2013; 104: 360-8.
11. Dan S, Okamura M, Seki M et al. Correlating phosphatidylinositol 3-kinase inhibitor efficacy with signaling pathway status: in silico and biological evaluations. Cancer Res 2010; 70: 4982-94.
12. Mashima T, Soma-Nagae T, Migita T et al. TRIB1 supports prostate tumorigenesis and tumor-propagating cell survival by regulation of endoplasmic reticulum chaperone expression. Cancer Res 2014; 74: 4888-97.
13. Arao T, Fukumoto H, Takeda M, Tamura T, Saijo N, Nishio K. Small in-frame deletion in the epidermal growth factor receptor as a target for ZD6474. Cancer Res 2004; 64: 9101-4.
14. Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID Bioinformatics Resources. Nat Protoc 2009; 4: 44-57.
15. Huang DW, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 2009; 37: 1-13.
16. Mashima T, Oh-hara T, Sato S et al. p53-defective tumors with a functional apoptosome-mediated pathway: a new therapeutic target. J Natl Cancer Inst 2005; 97: 765-77.
17. Sheppard KE, McArthur GA. The cell-cycle regulator CDK4: an emerging therapeutic target in melanoma. Clin Cancer Res 2013; 19: 5320-8.
18. Lens SM, Voest EE, Medema RH. Shared and separate functions of polo-like kinases and aurora kinases in cancer. Nat Rev Cancer 2010; 10: 825-41.
19. Curtin JC, Lorenzi MV. Drug discovery approaches to target Wnt signaling in cancer stem cells. Oncotarget 2010; 1: 552-66.
20. Soucy TA, Smith PG, Milhollen MA et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 2009; 458: 732-6.
21. Heisterkamp N, Stam K, Groffen J, de Klein A, Grosveld G. Structural organization of the bcr gene and its role in the Ph' translocation. Nature 1985; 315: 758-61.
22. Sakamoto H, Tsukaguchi T, Hiroshima S et al. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell 2011; 19: 679-90.
23. Chiang CT, Way TD, Lin JK. Sensitizing HER2-overexpressing cancer cells to luteolin-induced apoptosis through suppressing p21(WAF1/CIP1) expression with rapamycin. Mol Cancer Ther 2007; 6: 2127-38.
24. Kurata T. Amrubicin for the treatment of advanced lung cancer. Expert Opin Drug Metab Toxicol 2009; 5: 171-80.
25. De Smaele E, Ferretti E, Gulino A. Vismodegib, a small-molecule inhibitor of the hedgehog pathway for the treatment of advanced cancers. Curr Opin Investig Drugs 2010; 11: 707-18.
26. Marcu MG, Doyle M, Bertolotti A, Ron D, Hendershot L, Neckers L. Heat shock protein 90 modulates the unfolded protein response by stabilizing IRE1alpha. Mol Cell Biol 2002; 22: 8506-13.
27. Fribley A, Zeng Q, Wang CY. Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. Mol Cell Biol 2004; 24: 9695-704.
28. Tsutsumi S, Gotoh T, Tomisato W et al. Endoplasmic reticulum stress response is involved in nonsteroidal anti-inflammatory drug-induced apoptosis. Cell Death Differ 2004; 11: 1009-16.